Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
FDA approves Eli Lilly's Mounjaro for weight loss
06:31pm, Wednesday, 08'th Nov 2023
The Food and Drug Administration has approved Eli Lilly and Company's (LLY) Mounjaro, under the name Zepbound, for the treatment of obesity. Previously, Novo Nordisk's (NVO) Wegovy and Ozempic were th
FDA approval of Eli Lilly's Zepbound is a win for patients as Ozempic competitors boom
06:20pm, Wednesday, 08'th Nov 2023
Pharmaceutical companies are now racing to develop anti-obesity drugs, and experts say that could drive supply up, and price down. The U.S. Food and Drug Administration (FDA) announced Wednesday that
Eli Lilly Shares Hit All-Time High After FDA Approves Drug for Weight-Loss Treatment
06:10pm, Wednesday, 08'th Nov 2023
Eli Lilly (LLY) shares hit an all-time high Wednesday after the Food and Drug Administration (FDA) approved the drug maker's Zepbound injection to treat people who are obese or are overweight and also
Eli Lilly's Zepbound has a strong shot of being the biggest drug of all time: Guggenheim's Fernandez
03:41pm, Wednesday, 08'th Nov 2023
Guggenheim analyst Seamus Fernandez joins 'Power Lunch' to discuss Eli Lilly's latest drug to get FDA approval, whether it'll become the biggest-selling drug of all time, and who will be on the hook i
FDA Approves Diabetes Drug Mounjaro For Weight Loss Under Brand Name Zepbound
03:38pm, Wednesday, 08'th Nov 2023
Eli Lilly's Zepbound helped users lose up to 22.5% of their weight in clinical trials.
UK's MHRA authorises Eli Lilly's Mounjaro
03:22pm, Wednesday, 08'th Nov 2023
Britain's health regulator on Wednesday authorised Eli Lilly's diabetes drug Mounjaro for weight management and weight loss in the UK.
What to know about Eli Lilly's new obesity drug
03:04pm, Wednesday, 08'th Nov 2023
The U.S. Food and Drug Administration approved Eli Lilly's keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's popular weight-loss therapy Wegovy.
LLY stock jumps after FDA approves Eli Lilly's tirzepatide drug for weight loss
02:14pm, Wednesday, 08'th Nov 2023
Eli Lilly And Co's (NYSE: LLY) stock saw a notable surge, trading at $610.50, up 1.69% (+$10.14) today, following the Food and Drug Administration's (FDA) approval of their blockbuster drug tirzepatid
Eli Lilly Wins FDA Approval For Highly Anticipated Weight-Loss Drug
01:34pm, Wednesday, 08'th Nov 2023
The FDA approved a highly anticipated weight-loss drug from Eli Lilly on Wednesday. Eli Lilly stock rose less than 2% after the release.
U.S. FDA approves Lilly's weight-loss drug
12:35pm, Wednesday, 08'th Nov 2023
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's drug for weight loss, according to data on the agency's website, giving the drugmaker entry into a lucrative market that has cap
FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug
12:20pm, Wednesday, 08'th Nov 2023
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.
Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?
08:20am, Wednesday, 08'th Nov 2023
Eli Lilly now forecasts that it will have lower profits this year than previously projected. Usually, announcements of that type take the wind out of a stock's price.
Grab these 2 funds with rich 11%-12% yields while you can
07:18am, Wednesday, 08'th Nov 2023
With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:32am, Tuesday, 07'th Nov 2023
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This
03:44pm, Monday, 06'th Nov 2023
The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and Jo
